Alopecia Market Report 2026

The alopecia market size has grown steadily in recent years. It will grow from $11.48 billion in 2025 to $11.93 billion in 2026 at a compound annual growth rate (CAGR) of 3.9%. The growth in the historic period can be attributed to rising prevalence of alopecia worldwide, increasing dermatology clinic visits, limited treatment options historically, growing research in hair loss therapies, increasing cosmetic awareness.

The alopecia market size is expected to see steady growth in the next few years. It will grow to $14.29 billion in 2030 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to development of novel regenerative medicine therapies, technological advancements in lltt devices, growing adoption of personalized alopecia treatments, expansion of online pharmacy distribution channels, increasing investment in hair restoration research. Major trends in the forecast period include increasing adoption of pharmaceutical treatments for hair loss, rising use of low-level laser therapy (lllt) devices, growth in hair transplant procedures, expansion of regenerative medicine applications for alopecia, increasing awareness and access to homecare hair loss treatments.

The rising prevalence of hair loss is expected to drive the growth of the alopecia market in the coming years. Hair loss refers to the partial or complete shedding of hair from areas where it normally grows. Alopecia treatments assist patients by addressing various aspects of hair loss through promoting hair regrowth, creating personalized treatment plans, using combination therapies, and managing the physical effects of hair loss, all of which can have a substantial positive impact on emotional well-being and quality of life. For instance, in April 2023, according to data from the National Health Commission, a China-based executive department, over 250 million people in China experienced hair loss, with 42% of them aged between 26 and 30. Additionally, in February 2023, according to the Statistic Brain Research Institute, a US-based educational organization, roughly 40% of men are expected to experience visible hair loss by age 35. Therefore, the increasing prevalence of hair loss is fueling the growth of the alopecia market.

Major companies in the alopecia market are focusing on developing innovative products, such as oral JAK inhibitors, to improve treatment outcomes and provide faster, more sustained hair regrowth for patients with autoimmune-related hair loss. An oral JAK inhibitor is a targeted pharmacological agent that modulates immune-driven inflammation by blocking Janus kinase pathways involved in follicular damage. For instance, in July 2025, Sun Pharmaceutical Industries Limited, an India-based specialty generics and dermatology-focused pharmaceutical company, launched LEQSELVI (deuruxolitinib) in the United States. The therapy showed rapid clinical improvement, with a significant number of patients achieving meaningful scalp hair regrowth in as little as eight weeks. Its introduction provides a timely, evidence-supported treatment option for severe alopecia areata, expanding therapeutic choices for both clinicians and patients.

In March 2023, Sun Pharmaceutical Industries Limited, an India-based pharmaceutical company, acquired Concert Pharmaceuticals for $576 million. Through this acquisition, Sun Pharmaceutical aims to enhance its alopecia treatment portfolio and broaden its product offerings. Concert Pharmaceuticals Inc. is a US-based biopharmaceutical company focused on developing oral Janus kinase inhibitors as a treatment for alopecia areata.

Major companies operating in the alopecia market are Pfizer Inc., Johnson and Johnson Ltd., Merck and Co. Inc., Bayer AG, Novartis AG, Sanofi SA, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Allergan Plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Perrigo Company Plc, Dr. Reddy's Laboratories Ltd., Cipla Limited, Almirall S.A., Aclaris Therapeutics Inc., Curallux LLC, Theradome Inc., Lexington International LLC, Histogen Inc., Apira Science Inc.

North America was the largest region in the alopecia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alopecia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the alopecia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the alopecia market by increasing the cost of imported pharmaceutical formulations, low-level laser therapy devices, and hair transplant equipment. Segments such as lltt devices, hair transplant tools, and regenerative medicine kits are most affected, with asia-pacific and europe facing higher import duties. These tariffs have raised treatment costs and slowed equipment availability. On the positive side, tariffs encourage local manufacturing, innovation in device production, and investment in regional supply chains.

The alopecia market research report is one of a series of new reports that provides alopecia market statistics, including alopecia industry global market size, regional shares, competitors with a alopecia market share, detailed alopecia market segments, market trends and opportunities, and any further data you may need to thrive in the alopecia industry. This alopecia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Alopecia is a medical condition that refers to hair loss, which can occur naturally or be associated with disease or the use of certain medications. It may be localized or diffuse, temporary or permanent, and can affect both sexes and all age groups. Treatment for alopecia aims to slow, reverse, or manage hair loss and encourage hair regrowth in affected areas.

The main types of alopecia include alopecia areata, androgenetic alopecia, alopecia totalis, traction alopecia, cicatricial alopecia, and others. Alopecia areata is an autoimmune disorder characterized by sudden hair loss that forms round or oval patches on the scalp or other parts of the body. Treatments include pharmaceuticals, low-level laser therapy devices, hair transplants, regenerative medicine, and others. Both males and females are affected. These treatments are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels, and are used by end-users such as dermatology clinics, home care settings, and others.

The alopecia market consists of revenues earned by entities by providing anagen effluvium, telogen effluvium, and alopecia universalis treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The alopecia market also includes the sales of shampoos, drugs, and hair regrowth supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.